LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 4 of 497
Next
>>
>
76 to 100 of 12420 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	WZ-4-145	0.04	uM	LJP6	1	J24	72	hr	1657	4532	5505	0.8232	0.7470
BT-20	WZ-4-145	0.04	uM	LJP6	2	J24	72	hr	1657	5171	5505	0.9392	0.9130
BT-20	WZ-4-145	0.04	uM	LJP6	3	J24	72	hr	1657	4365	5505	0.7928	0.7036
BT-20	XMD16-144	0.04	uM	LJP5	1	M12	72	hr	1657	5505	5505	0.9999	0.9998
BT-20	XMD16-144	0.04	uM	LJP5	2	M12	72	hr	1657	5380	5505	0.9772	0.9673
BT-20	XMD16-144	0.04	uM	LJP5	3	M12	72	hr	1657	5296	5505	0.9619	0.9455
BT-20	Brivanib	0.04	uM	LJP5	1	P18	72	hr	1657	5186	5505	0.9419	0.9169
BT-20	Brivanib	0.04	uM	LJP5	2	P18	72	hr	1657	5432	5505	0.9866	0.9809
BT-20	Brivanib	0.04	uM	LJP5	3	P18	72	hr	1657	5180	5505	0.9409	0.9154
BT-20	Buparlisib	0.04	uM	LJP5	1	H06	72	hr	1657	5360	5505	0.9735	0.9621
BT-20	Buparlisib	0.04	uM	LJP5	2	H06	72	hr	1657	6017	5505	1.0929	1.1329
BT-20	Buparlisib	0.04	uM	LJP5	3	H06	72	hr	1657	5691	5505	1.0337	1.0482
BT-20	BX-912	0.04	uM	LJP5	1	L24	72	hr	1657	5146	5505	0.9347	0.9065
BT-20	BX-912	0.04	uM	LJP5	2	L24	72	hr	1657	4795	5505	0.8709	0.8153
BT-20	BX-912	0.04	uM	LJP5	3	L24	72	hr	1657	5249	5505	0.9534	0.9333
BT-20	Canertinib	0.04	uM	LJP6	1	H12	72	hr	1657	4887	5505	0.8876	0.8392
BT-20	Canertinib	0.04	uM	LJP6	2	H12	72	hr	1657	4592	5505	0.8341	0.7626
BT-20	Canertinib	0.04	uM	LJP6	3	H12	72	hr	1657	5178	5505	0.9405	0.9149
BT-20	Celastrol	0.04	uM	LJP6	1	G12	72	hr	1657	5726	5505	1.0400	1.0573
BT-20	Celastrol	0.04	uM	LJP6	2	G12	72	hr	1657	5735	5505	1.0417	1.0596
BT-20	Celastrol	0.04	uM	LJP6	3	G12	72	hr	1657	6025	5505	1.0943	1.1350
BT-20	CGP60474	0.04	uM	LJP5	1	F06	72	hr	1657	5365	5505	0.9745	0.9634
BT-20	CGP60474	0.04	uM	LJP5	2	F06	72	hr	1657	5895	5505	1.0707	1.1012
BT-20	CGP60474	0.04	uM	LJP5	3	F06	72	hr	1657	5313	5505	0.9650	0.9499
BT-20	CGP60474	0.04	uM	LJP6	1	G06	72	hr	1657	1166	5505	0.2118	-0.1278

|<
<<
Previous
Page 4 of 497
Next
>>
>
76 to 100 of 12420 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)